---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-013165"
form_type: "8-K"
ticker: "CLSDQ"
cik: "0001539029"
company_name: "Clearside Biomedical, Inc."
filed_at: "2023-04-18T23:59:59+00:00"
generated_at: "2026-06-17T00:42:49.946941+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Clearside Biomedical announces plans for Phase 2b ODYSSEY trial of CLS-AX in wet AMD

## Summary
- Phase 2b trial ODYSSEY to enroll 60 patients with wet AMD; 2:1 randomization CLS-AX vs aflibercept.
- Primary outcome: mean change in BCVA from baseline to Week 36; secondary include CST and treatment burden.
- CLS-AX arm: 3 aflibercept loading doses + CLS-AX at baseline, then at least every 24 weeks.
- Enrollment starts Q2 2023; topline results expected in Q3 2024.

## SEC filing metadata
- accession: 0000950170-23-013165
- form_type: 8-K
- ticker: CLSDQ
- cik: 0001539029
- company_name: Clearside Biomedical, Inc.
- filed_at: 2023-04-18T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1539029/000095017023013165/0000950170-23-013165-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1539029/000095017023013165/clsd-20230418.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-013165
- JSON: https://secwatch.observer/filing/0000950170-23-013165.json
- Plain text: https://secwatch.observer/filing/0000950170-23-013165.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.